As the COVID-19 virus permeates more corners of the world, lawyers anticipate an increase in litigation related to the scope of patents for treatments and vaccines.

Lawyers at Spain-based global firm ECIJA say the granting of a patent in favor of a specific organization could possibly undermine the development and wide-scale distribution of virus treatments. Barring intervention by an international health authority, countries may turn to other means to secure diagnostic tools, treatments and vaccines, they say.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]